Equine Melanoma Study Guide

Overview and Clinical Importance

Equine melanoma is a tumor arising from abnormal proliferation of melanocytes, the pigment-producing cells of the skin. Unlike in humans, equine melanomas are not associated with ultraviolet light exposure. Melanomas represent the third most common skin tumor in horses (after sarcoids and squamous cell carcinoma), with an incidence of approximately 80% in gray horses over 15 years of age. Understanding the genetics, classification, diagnosis, and treatment options is essential for NAVLE success.

Etiology and Pathogenesis

Genetic Basis: The Gray Gene and STX17 Mutation

The development of melanoma in gray horses is linked to a 4.6-kb duplication in intron 6 of the Syntaxin 17 (STX17) gene. This same mutation causes the progressive graying of the coat. The gray gene is an autosomal dominant trait affecting chromosome region containing STX17, NR4A3, TXNDC4, and INVS genes.

Key genetic concepts for the NAVLE:

• G2 allele (2 copies of duplication): Slow graying, LOWER melanoma risk
• G3 allele (3 copies of duplication): Fast graying, HIGHER melanoma risk
• Homozygous gray horses (GG) have higher melanoma incidence than heterozygous (Gg)
• ASIP mutation (loss-of-function) combined with STX17 mutation increases melanoma likelihood

Coat Color and Melanoma Risk

Breed Predispositions

Breeds commonly affected due to high prevalence of gray coat color:

• Lipizzaners: 50% incidence; 94% in horses over 16 years
• Arabians: High prevalence; often fast-graying
• Percherons: Commonly affected
• Andalusians: High prevalence
• Quarter Horses: Lower prevalence (17.7%); may have protective genetic factors

Classification of Equine Melanocytic Tumors

Valentine's classification (1995) remains the standard system for categorizing equine melanocytic tumors. This system recognizes four distinct clinical syndromes based on clinical presentation, histopathology, and biological behavior.

Anatomic Locations and Clinical Signs

Common Anatomic Sites

Melanomas occur in characteristic locations. More than 50% of melanomas are located in the perineal region.

Typical Clinical Presentation

Gross Appearance: Firm, black, dome-shaped nodules. May be solitary or multiple. Usually hairless. Size ranges from less than 1 cm to larger than a fist. May ulcerate and become infected with chronicity.

Clinical Signs: Vary based on location and size. Early lesions are often asymptomatic and found incidentally. Advanced disease causes functional impairment depending on location.

Diagnosis

Clinical Diagnosis

Melanomas are often diagnosed based on signalment, location, and characteristic gross appearance. In most cases, the distinctive black pigmented nodules in classic locations in a gray horse are pathognomonic.

Fine Needle Aspirate (FNA) and Cytology

FNA is a minimally invasive diagnostic technique that can confirm melanocytic origin:

• Cytologic findings: Heavily pigmented cells with dark melanin granules
• Malignancy criteria: Anisocytosis, anisokaryosis, multinucleation, variable N:C ratio, nuclear molding
• Limitation: Heavy pigmentation may obscure nuclear detail; potassium permanganate bleaching may be needed

Histopathology

Histopathology remains the gold standard for definitive diagnosis and differentiation between tumor types:

• Melanocytic nevus: Epidermal or superficial dermal involvement; well-differentiated
• Dermal melanoma/melanomatosis: Deep dermal/subcutaneous location; round pigmented cells; variable margins
• Anaplastic malignant melanoma: Poorly differentiated; pleomorphic; infiltrative; vascular invasion; mitotic figures

Immunohistochemistry

Used for amelanotic melanomas or when differentiation from other tumors is needed. Important markers for equine melanoma:

Additional Diagnostics for Staging

For evaluation of metastatic disease:

• Rectal palpation: Internal masses, enlarged lymph nodes
• Transrectal/abdominal ultrasound: Internal melanomas, sublumbar lymph node assessment
• Thoracic radiography/ultrasound: Pulmonary metastases, pleural effusion
• Endoscopy: Guttural pouch involvement (especially with parotid region tumors)

Differential Diagnosis

Other conditions to consider with black nodular skin masses:

• Nodular sarcoid (may have superficial pigmentation)
• Cutaneous lymphoma/lymphosarcoma
• Hemangioma
• Mast cell tumor
• Fibroma
• Parasitic cysts/granulomas (Gasterophilus spp.)

Treatment Options

There is no uniformly effective treatment for equine melanoma. Treatment selection depends on tumor size, location, number, and owner goals. Early intervention with small tumors yields the best outcomes.

Treatment Protocol Details

Cisplatin Protocol

• Dosage: 1 mg cisplatin per cubic centimeter of tumor tissue
• Schedule: 4 treatments at 2-week intervals
• Formulation: Cisplatin in sesame oil or biodegradable beads for controlled release
• Efficacy: 77-92% relapse-free survival at 1-4 years (tumors less than 2 cm)

Cimetidine Protocol

• Dosage: 2.5-3.5 mg/kg PO twice to three times daily
• Duration: Minimum 3 months; maintenance therapy if effective
• Response: Variable; some studies report 50-90% reduction, others show no effect

ONCEPT Vaccine Protocol (Off-label)

• Initial series: 4 doses at 2-week intervals (transdermal injection)
• Boosters: Every 6 months if effective
• Response rates: ~50% tumor regression, ~40% stabilization, ~10% no effect

Prognosis

Important: Despite the high incidence of melanomas in gray horses, there is no evidence that gray horses have shorter lifespans than non-gray horses. Many horses live comfortably with melanomas for years.